Results

Total Results: 723 records

Showing results for "diabetes treatment".
Users also searched for: diabetes guidelines

281. Medicare-Medication-Use Research (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/medicare-medication-use_research.pdf
     April 01, 2014 - Medicare beneficiaries with both medical and psychiatric conditions likely experi- ences complexity in treatment … The Medicare drug benefit (Part D) and treatment of heart failure in older adults. … Effects of Medicare Part D coverage gap on medication and medical treatment among elderly beneficiaries … Partnerships/downloads/11522-P.pdf Data Points • #19 • Medication Use in Medicare 14 Appendix A: Part D therapeutic … Antiparkinson agents Central nervous system agents Antianxiety agents Neuromuscular drugs Musculoskeletal therapy

282. Glaucoma-Treatment Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/glaucoma-treatment_executive.pdf
     April 01, 2012 - Medical Treatment of Open-Angle Glaucoma KQ1a: Comparative Effectiveness of Medical Treatments for … Reducing Visual Impairment • No studies of medical therapy were identified that directly addressed … Circadian Intraocular Pressure • Our conclusions regarding the effect of topical therapies in lowering … Given the slowly progressive nature of glaucoma, the large trials of glaucoma therapy have demonstrated … any significant conclusions about the comparative effectiveness of most currently used therapies.

283. CER 45 Self-Measured Blood Pressure Monitoring Comparative Effectiveness Surveillance Final 4.7.16 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/measuring-blood-pressure-surveillance-160412.pdf
     October 08, 2025 - "Sleep'time" blood"pressure"as"a"therapeutic"target"for"cardiovascular"risk"reduction"in"type"2"diabetes … Sleep'time"ambulatory"blood"pressure"as"a"novel"therapeutic"target"for" cardiovascular"risk"reduction … Home"blood"pressure"and"cardiovascular"outcomes"in"patients"during" antihypertensive"therapy:"primary"results"of"HONEST … Efficacy" and"safety"of"aliskiren"and"amlodipine"combination"therapy"in"patients"with"hypertension:" … received$home$BP$telemonitors$and$transmitted$BP$data$to$pharmacists$who$adjusted$ antihypertensive$therapy

284. S16 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s16.pdf
     October 01, 2007 - of individual patients or weighing the implications of particular poli- cies affecting medical therapies … clinical and policy decisions at different levels of the health care system, as illustrated in Table 1 for treatments … randomization provides against sources of bias and confounding that often affect observational studies, where treatments … Decisions Relevant to Medical Therapies (Example: Therapy for Osteoporosis) Drug approval—Is slow release … is equally effective in patients with diabetes and nondiabetics on a relative scale (roughly 25% reduction

285. 13-MDM347013 30..38 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/whitepaper4-bossuyt02262010-2.pdf
     January 01, 2009 - may extend into the longer term.11 A randomized trial of blood glucose self-monitoring among type 2 diabetes … perceptions or illness cognitions have been shown to affect adherence behavior among patients with HIV, diabetes … Clinicians use tests to increase their diagnostic and therapeutic confidence. … Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON … How do patients’ treatment preferences compare with those of clinicians?

286. 13-MDM347013 30..38 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/outcomes-testing-evaluation_research.pdf
     January 01, 2009 - may extend into the longer term.11 A randomized trial of blood glucose self-monitoring among type 2 diabetes … perceptions or illness cognitions have been shown to affect adherence behavior among patients with HIV, diabetes … Clinicians use tests to increase their diagnostic and therapeutic confidence. … Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON … How do patients’ treatment preferences compare with those of clinicians?

287. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/pressure-ulcer-prevention_research-protocol.pdf
     January 10, 2012 - By one estimate, treatment costs may be as much as 2.5 times the cost of prevention. 1 A number of … impairment; body weight; nutritional status; incontinence; or specific medical comorbidities, such as diabetes … age, race or skin tone, physical impairment, body weight, or specific medical comorbidities (e.g., diabetes … www.effectivehealthcare.ahrq.gov Published Online: January 10, 2012 6 comorbidities (e.g., diabetes … Waterlow pressure ulcer prevention/treatment policy card. Revised 2005.

288. Medication-Therapy-Management Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/medication-therapy-management_executive.pdf
     November 01, 2014 - object is to help consumers, health care providers, and others in making informed choices among treatment … Effectiveness Reviews, the program supports systematic appraisals of existing scientific evidence regarding treatments … patient (i.e., a systematic process of collecting patient-specific information, assessing medication therapies … substitution issue; complex regimen that can be simplified with same therapeutic benefit; and potential … for hypertension and dyslipidemia Insufficient for treatment of patients with diabetes, depression

289. Version-3-Immunity-After-Covid-19-Appendix-Table-B-1 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/version-3-immunity-after-COVID-19-appendix-table-B-1.xlsx
     January 24, 2022 - analysis Death within the first 3 months after SARS-CoV-2 infection, active chemotherapy, previous therapy … were included in this analysis Death within the first 3 months after SARS-CoV-2 infection, previous therapy … radiological suspicion of infection, cancer patients at high risk for infection and eligible for active therapy … Severe Obesity: 5 (3.1)* Immunosuppresssed (e.g., HIV, autoimmune disease): 2 (1.3)* Immune-weakening therapy … sample was taken) Median (IQR) days from symptom onset to testing: 6 (3-9) Asymptomatic: 34* (19.2)* Treatment

290. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/juvenile-arthritis-dmards_executive.pdf
     September 01, 2011 - JIA is an important cause of chronic disease in childhood, with prevalence similar to type I diabetes … There is no cure for JIA, but over the past 25 years new therapies have provided great advances in treatment … includes multiple categories, which could potentially respond differentially to therapy. … definitions for, and systematic ascertainment and reporting of, adverse events possibly associated with therapeutic … our ability to detect promising new treatments.

291. Kidney-Stone-Prevention Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/kidney-stone-prevention_executive.pdf
     March 01, 2013 - stones also may be increased by medical conditions such as primary hyperparathyroidism,18 obesity,19 diabetes … with placebo, usual care/no treatment, or other available active treatments. … when added to this diet therapy. … important clinical subgroups included (e.g., gender, single vs. multiple past stone episodes, obesity, diabetes … Diabetes mellitus and the risk of nephrolithiasis. Kidney International. 2005 Sep;68(3):1230-5.

292. Outcome Measure Framework Design Document (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/registry-of-patient-registries_research-2014.pdf
     January 01, 2014 - purposes for patient registries include evaluating the safety, effectiveness, or quality of medical treatments … Examples of outcome measures Title Definition Type Response to rituximab treatment Reduction of … For example, an important outcome measure in diabetes care is management of HbA1c. … Members 18 - 75 years of ages with diabetes. … Patient French AutoImmunity and Rituximab (AIR) Registry Response to rituximab treatment, as measured

293. Future Research Needs for First- and Second-Generation Antipsychotics for Children and Young Adults (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/antipsychotics-children-future_research.pdf
     February 01, 2012 - adolescents (10–17 years) Bipolar disorder (depression) Adults Bipolar disorder (maintenance) Adjunctive therapy … with other therapies, there is a paucity of data regarding the efficacy and effectiveness of 1st or … Large prospective cohort designs that follow youth with a range of mental health disorders and treatments … adolescents (10–17 years) Bipolar disorder (depression) Adults Bipolar disorder (maintenance) Adjunctive therapy … An RCT has to be large, because the question compares active treatments, and the effect size may be

294. Disposition of Comments Report for CER 132 Combination Therapy Versus Intensification of Statin Monotherapy: An Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/high-cholestorol-medicines-update_disposition-comments.pdf
     September 01, 2014 - baseline target from which to go forward and randomize treatments. … What about harms associated with intensive statin therapy such as diabetes or rhabdomyolysis What … For example, intensive statin therapy has been associated with an increased risk of diabetes compared … Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.JAMA … In addition to therapeutic lifestyle changes, a moderate or high dose of a statin therapy should be

295. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/angina-heart-attack-treatments_research-protocol.pdf
     December 11, 2012 - The cornerstone of short- and long-term treatment in all cases is medical therapy with antiplatelet … ) ○ Adverse effects of treatments 1. … Postdischarge treatment KQ 1 KQs 1, 2, 3 Individual characteristics • Age • Sex • Diabetes • Weight … , anticoagulant therapy, and combined therapies were published. … currently in use (such as specific components of treatments considered to be “optimal medical therapy

296. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cystic-fibrosis-hgh_executive.pdf
     October 01, 2010 - Effectiveness Reviews, the program supports systematic appraisals of existing scientific evidence regarding treatments … outcomes, including frequency of required intravenous antibiotic treatments, frequency of hospitalization … duration, baseline nutritional status, and concurrent medical therapies? … (gender, age, ethnicity, nutritional status); comorbidities; and use of concurrent standard medical therapies … The usage of concurrent medical therapies in patients enrolled in trials evaluating rhGH therapy was

297. PHARMACO-EPIDEMIOLOGIC METHODS FOR A STUDY OF (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/antipsychotic-medicine-cardiovascular-elderly_research.pdf
     February 01, 2009 - Diabetes was defined by the presence of diagnoses plus use of anti-diabetic medications. … Discussion In this study of over 20,000 elderly patients initiating APM treatments, use of conventional … Clin Therapeutics 2002;24(9):1466-76. 5. Chan YC, Pariser SF, Neufeld G. … arrhythmia 1.4 1.4 Cerebrovascular disease 29.1 30.9 CHF 32.6 31.1 Diabetes … *Controlled for calendar year, age, gender, race, prior arrhythmias, cerebrovascular disease, CHF, diabetes

298. Presentation of Future Research Needs (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/presentations-future_research.pdf
     April 01, 2012 - These eight reports were: Prioritizing Research Needs in Gestational Diabetes Mellitus (Johns Hopkins … 20 Inhaled Nitric Oxide Therapy for Premature Infants. … treatment to an existing treatment after treatment failure Initial treatment with psychosocial … and/or pharmacologic treatments or Continuation of existing treatment without addition of psychosocial … Future Research Needs for the Management of Gestational Diabetes.

299. Grades-Predictive-Values White-Paper-2015 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/grades-predictive-values_white-paper-2015.pdf
     January 01, 2015 - Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone … Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. … Spinal manipulative therapy for chronic low-back pain. … Insulin detemir versus insulin glargine for type 2 diabetes mellitus. … Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis

300. Medical Care Journal Supplement (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/toc.pdf
     January 01, 2007 - Improving Depiction of Benefits and Harms: Analyses of Studies of Well-known Therapeutics and Review … Can Between-Physician Differences in Prescribing Patterns Be Used to Estimate Treatment Effects? … Heterogeneity and Treatment Effect Estimates from Risk-Adjustment and Instrumental Variable Methods … Constantine Frangakis Using Propensity Scores Subclassification to Estimate Effects of Longitudinal Treatments … : An Example Using a New Diabetes Medication.